- Home
- TVGN vs ZTG Comparison
TVGN vs ZTG Comparison
Compare TVGN & ZTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | ZTG |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Macau |
| Employees | N/A | N/A |
| Industry | Blank Checks | Professional Services |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 20.4M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | TVGN | ZTG |
|---|---|---|
| Price | $7.81 | $1.82 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 4.1M |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.60 |
| 52 Week High | $12.03 | $12.25 |
Technical Indicators
Market Signals| Indicator | TVGN | ZTG |
|---|---|---|
| Relative Strength Index (RSI) | 67.37 | 50.03 |
| Support Level | $6.22 | $0.68 |
| Resistance Level | $7.90 | $12.25 |
| Average True Range (ATR) | 0.41 | 0.27 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 88.98 | 72.07 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.